You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Hematologic Malignancies

TUMOR LYSIS SYNDROME IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A NEPHROLOGY PERSPECTIVE IN RESOURCE-LIMITED SETTINGS

  • 1. Alexandria University Faculty of Medicine, Alexandria, Egypt

  • 2. College of Medicine and Health Science, Sultan Qaboos University, Muscat, Oman

The final, formatted version of the article will be published soon.

Abstract

Background: Tumor lysis syndrome (TLS) is a major metabolic emergency in pediatric oncology and a leading cause of acute kidney injury (AKI) in children with hematological malignancies. Early identification of children at risk for severe AKI remains challenging. Methods: This retrospective study included 50 children with laboratory or clinical TLS diagnosed according to the Howard–Pui classification. Serial biochemical parameters were analyzed over a 10-day period. AKI severity was classified using the pediatric Risk, Injury, Failure, Loss, End-stage renal disease (pRIFLE) criteria based on changes in estimated glomerular filtration rate (eGFR). Clinical characteristics, biochemical trends (especially phosphate and uric acid), and outcomes were compared between children with mild (pRIFLE 0 [no AKI]/R/I) and severe (pRIFLE-F) AKI. Results: Twenty-seven patients had acute lymphoblastic leukemia (ALL), and 23 had lymphoma, mainly Burkitt's lymphoma. Clinical TLS accounted for 86% of cases, and 60% of children developed severe AKI. Severe AKI was significantly associated with spontaneous TLS onset, prolonged TLS duration, increased need for kidney replacement therapy, intensive care admission, and higher mortality. Static demographic characteristics, malignancy type, tumor burden, and radiological findings did not differ between AKI severity groups. While hyperphosphatemia and hyperuricemia were common, dynamic phosphate changes showed the strongest association with AKI severity. The daily rise in serum phosphate before AKI onset demonstrated good discriminatory performance for predicting severe AKI (AUC 0.839), outperforming changes in uric acid. Conclusion: In pediatric TLS, AKI severity is the main determinant of clinical outcome. Dynamic phosphate kinetics (Delta phosphorus), rather than static biochemical thresholds, represent a robust early biomarker for identifying children at risk of severe AKI and may improve risk stratification, particularly in resource-limited settings.

Summary

Keywords

Acute Kidney Injury, Febuxostat, Kidney replacement therapy, phosphate dynamics, Rasburicase, Tumor Lysis Syndrome

Received

31 December 2025

Accepted

17 February 2026

Copyright

© 2026 Elshafey, Essa, Zaid, Wali and El Chazli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yasser Wali

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Share article

Article metrics